Australia markets closed

Akero Therapeutics, Inc. (AKRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.71-0.37 (-1.84%)
At close: 04:00PM EDT
20.55 +0.84 (+4.26%)
After hours: 04:37PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.36B
Enterprise value 837.88M
Trailing P/E 8.18
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.54
Enterprise value/revenue N/A
Enterprise value/EBITDA -5.64

Trading information

Stock price history

Beta (5Y monthly) -0.38
52-week change 3-56.33%
S&P500 52-week change 322.43%
52-week high 358.38
52-week low 311.25
50-day moving average 324.41
200-day moving average 328.32

Share statistics

Avg vol (3-month) 31.4M
Avg vol (10-day) 3696.19k
Shares outstanding 569.15M
Implied shares outstanding 669.15M
Float 846.07M
% held by insiders 15.71%
% held by institutions 192.35%
Shares short (15 Apr 2024) 48.18M
Short ratio (15 Apr 2024) 47.54
Short % of float (15 Apr 2024) 412.19%
Short % of shares outstanding (15 Apr 2024) 411.83%
Shares short (prior month 15 Mar 2024) 49.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-23.07%
Return on equity (ttm)-35.22%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -172.84M
Net income avi to common (ttm)-151.76M
Diluted EPS (ttm)-2.89
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)550.01M
Total cash per share (mrq)9.77
Total debt (mrq)26.04M
Total debt/equity (mrq)4.86%
Current ratio (mrq)29.27
Book value per share (mrq)9.60

Cash flow statement

Operating cash flow (ttm)-145.37M
Levered free cash flow (ttm)-93.79M